Bob Johnson
CH.com Alumnus
 
Offline

"Only the educated are free." -Epictetus
Posts: 5965
Kennett Square, PA (USA)
Gender:
|
Found a couple of old files while looking for some options for you:
Frovatriptan for the treatment of cluster headaches CEPHALALGIA 2004; 24:1045-1048
Report of a small study done at Jefferson headache clinic, Philadelphia, using Frovatriptan as an added preventive medication in addition to Verapamil. It involved 17 patients and there are no other studies, to date, to give comparative experiences but it's an approach when the regular therapies are not working.
If you are not having inadequate response to your present meds you might give your doc a copy of this message. _______________________________________________ [Member response to this report.]
Re: Frovatriptan as added preventive med. Reply #3 - [82/09] at 10:57am From my point of view I would like to add that I have had good to excellent success with Frovatriptan as an added preventative medication. Added in addition to 2 x 120 mg Verapamil SR per day, which works good for me most time of the year.
In Dec. 2008 I tried Frovatriptan and got almost pain free with 3 x 2,5 mg per day, one tablet taken every 8 hours. (My body weight is 106 kg) Frova took appr. 2 days to work good.
A couple of weeks ago my cluster headaches went worse and I started with 3 x 2,5 mg/day Frovatriptan again. Same good result as in Dec. 2008: Pain free after two days, just one "little" CH attack per night, during the first two nights.
After five days I stopped taking Frova, a couple of CH attacks came over the weekend but since then not much.
I prefer to use Frova as an additional preventative, rather than to "wait" for CH attacks and abort them with Sumatriptan s.c. Oxygen works very good for me to abort CH attacks.
With Frova I did not notice ANY side effects. In Dec. 2008 blood pressure and ECG were checked after two weeks of taking Frova: Normal results.
My headache specialist agreed to the 3 x 2,5 mg Frova treatment, but recommended regular BP and ECG monitoring.
I have not tried Naratriptan or Eletriptan. ================== Headache. 2004 Apr;44(4):361-4.
Eletriptan for the short-term prophylaxis of cluster headache.
Zebenholzer K, Wober C, Vigl M, Wessely P.
Department of Neurology, University of Vienna (Austria) Medical School.
BACKGROUND: A beneficial prophylactic effect from eletriptan 40 mg given to a single patient with cluster headache was observed. OBJECTIVE: To further evaluate the efficacy of eletriptan in the short-term prophylaxis of cluster headache. METHODS: We treated 18 patients; mean age, 40.5 years (standard deviation [SD], 9.9). The number of cluster headache attacks was recorded during a baseline period of 6 days, and during 6 days of treatment with eletriptan 40 mg twice daily. The primary outcome measure was the reduction in the number of attacks during the treatment period. RESULTS: In the 16 patients who completed the study (2 patients were lost to follow-up), the mean total number of attacks decreased from 10.9 (SD, 5.6) during baseline to 6.3 (SD, 3.7) during treatment with eletriptan (P=.01) The reduction in the number of attacks exceeded 50% in 6 patients. CONCLUSION: This small open-label study suggests that eletriptan 40 mg twice daily may be useful for the short-term prophylaxis of cluster headache.
PMID: 15109360 [PubMed - in process ======== ========
Sometimes a change of the class of meds you are using is useful, here, away from the triptans to:
Headache 2001 Sep;41(8):813-6
Olanzapine as an Abortive Agent for Cluster Headache.
Rozen TD.
Department of Neurology, Jefferson Headache Center/Thomas Jefferson University Hospital, Philadelphia, Pa.
OBJECTIVE: To evaluate olanzapine as a cluster headache abortive agent in an open-label trial. BACKGROUND: Cluster headache is the most painful headache syndrome known. There are very few recognized abortive therapies for cluster headache and fewer for patients who have contraindications to vasoconstrictive drugs. METHODS: Olanzapine was given as an abortive agent to five patients with cluster headache in an open-label trial. THE INITIAL OLANZAPINE DOSE WAS 5 MG, AND THE DOSE WAS INCREASED TO 10 MG IF THERE WAS NO PAIN RELIEF. THE DOSAGE WAS DECREASED TO 2.5 MG IF THE 5-MG DOSE WAS EFFECTIVE BUT CAUSED ADVERSE EFFECTS. To be included in the study, each patient had to treat at least two attacks with either an effective dose or the highest tolerated dose. RESULTS: Five patients completed the investigation (four men, one woman; four with chronic cluster, one with episodic cluster). Olanzapine reduced cluster pain by at least 80% in four of five patients, and TWO PATIENTS BECAME HEADACHE-FREE AFTER TAKING THE DRUG. Olanzapine typically alleviated pain within 20 minutes after oral dosing and treatment response was consistent across multiple treated attacks. The only adverse event was sleepiness. CONCLUSIONS: Olanzapine appears to be a good abortive agent for cluster headache. IT ALLEVIATES PAIN QUICKLY AND HAS A CONSISTENT RESPONSE ACROSS MULTIPLE TREATED ATTACKS. IT APPEARS TO WORK IN BOTH EPISODIC AND CHRONIC CLUSTER HEADACHE.
PMID 11576207 PubMed
--------------------------------------------------------------------------------
Olanzapine has a brand name of "Zyprexa" and is a antipsychotic. Don't be put off by this primary usage. Several of the drugs used to treat CH are cross over applications, that is, drugs approved by the FDA for one purpose which are found to be effective with unrelated conditions--BJ. ------------ A number of us have excellent results with this as an abortive but, notice in the abstract, in a few individuals it stopped the cycle. ========
A few men here have given some highly positive reports on this approach:
Headache. 2006 Jun;46(6):925-33.
Testosterone replacement therapy for treatment refractory cluster headache.
Stillman MJ.
Objectives.-To describe the clinical characteristics and laboratory findings of cluster headache patients whose headaches responded to testosterone replacement therapy. Background.-Current evidence points to hypothalamic dysfunction, with increased metabolic hyperactivity in the region of the suprachiasmatic nucleus, as being important in the genesis of cluster headaches. This is clinically borne out in the circadian and diurnal behavior of these headaches. For years it has been recognized that male cluster headache patients appear overmasculinized. Recent neuroendocrine and sleep studies now point to an association between gonadotropin and corticotropin levels and hypothalamically entrained pineal secretion of melatonin. Results.-Seven male and 2 female patients, seen between July 2004 and February 2005, and between the ages of 32 and 56, are reported with histories of treatment resistant cluster headaches accompanied by borderline low or low serum testosterone levels. The patients failed to respond to individually tailored medical regimens, including melatonin doses of 12 mg a day or higher, high flow oxygen, maximally tolerated verapamil, antiepileptic agents, and parenteral serotonin agonists. Seven of the 9 patients met 2004 International Classification for the Diagnosis of Headache criteria for chronic cluster headaches; the other 2 patients had episodic cluster headaches of several months duration. After neurological and physical examination all patients had laboratory investigations including fasting lipid panel, PSA (where indicated), LH, FSH, and testosterone levels (both free and total). All 9 patients demonstrated either abnormally low or low, normal testosterone levels. After supplementation with either pure testosterone in 5 of 7 male patients or combination testosterone/estrogen therapy in both female patients, the patients achieved cluster headache freedom for the first 24 hours. Four male chronic cluster patients, all with abnormally low testosterone levels, achieved remission. Conclusions.-Abnormal testosterone levels in patients with episodic or chronic cluster headaches refractory to maximal medical management may predict a therapeutic response to testosterone replacement therapy. In the described cases, diurnal variation of attacks, a seasonal cluster pattern, and previous, transient responsiveness to melatonin therapy pointed to the hypothalamus as the site of neurological dysfunction. Prospective studies pairing hormone levels and polysomnographic data are needed.
PMID: 16732838
|